ZIM Laboratories Limited has informed the Exchange regarding the outcome of the Board meeting held on August 07, 2025.
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zim Laboratories' Board met on August 7, 2025 and approved Q1 FY26 (quarter ended June 30, 2025) unaudited results along with three other decisions. On a consolidated basis, revenue from operations fell to ₹7,175.61 lakhs from ₹8,182.44 lakhs in Q1 FY25, a drop of about 12%. The company swung to a consolidated loss before tax of ₹(243.20) lakhs versus a profit of ₹123.44 lakhs last year, and a loss after tax of ₹(187.49) lakhs (EPS of ₹(0.38)) compared to a profit of ₹89.83 lakhs (EPS of ₹0.18). Standalone numbers also slipped into a loss of ₹(169.19) lakhs versus a ₹75.90 lakh profit a year ago. Additionally, the Board appointed Protiviti India as Internal Auditor for FY 2025-26 (continuation from FY 2019-20), approved an investment of up to AED 4,50,000 (~₹1 crore) in Dubai-based step-down subsidiary ZIM Scientific Office L.L.C. for GCC business expansion, and approved the closure of another step-down subsidiary ZIM Laboratories Middle East DMCC (which had nil turnover).
The results are weak – revenue declined and the company posted a consolidated loss versus a profit in the same quarter last year, which is likely to weigh negatively on the stock. The subsidiary investment in the GCC region signals expansion plans, while the closure of the nil-revenue DMCC unit is a minor restructuring step with no material financial impact.